Figure 1. Median Overall Survival (95% CIs) Comparing Surveillance, Epidemiology, and End Results (SEER)–Medicare Patients and Clinical Trial Intervention Arm Participants Receiving the Same US Food and Drug Administration–Approved Cancer Drug for the Same Indication (2008-2013).

Nab indicates nanoparticle albumin-bound; NSCLC, non–small cell lung cancer.

^aUpper confidence bound not met.